NCT05203510

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction)

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: United Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Parenteral Treprostinil	Parenteral treprostinil will be administered per schedule specified in the arm description.
DRUG	Oral Treprostinil	Oral treprostinil will be administered per schedule specified in the arm description.

Timeline

• Start date: 2022-10-20
• Primary completion: 2026-04-30
• Completion: 2028-04-30
• First posted: 2022-01-24
• Last updated: 2025-12-09

Locations

28 sites across 1 country: United States

Regulatory

• FDA-regulated drug study